Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consens

Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on regis

Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates

RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for In

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK

RESEARCH TRIANGLE PARK, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD)

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“O

Opus Genetics NASDAQ: IRD is advancing a portfolio of gene therapies for inherited retinal diseases,

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“O

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.75 per share versus the Zacks Consens

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcomin

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients,

Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms

RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“O

RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades and downg